Wells Fargo
CTNM

Wells Fargo’s Contineum Therapeutics CTNM Stock Holding History

Wells Fargo’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
+22,510
New +$295K ﹤0.01% 4824
2025
Q4 		– Sell
-5,359
Closed -$63K – 7394
2025
Q3 		$63K Sell
5,359
-2,184
-29% -$17.6K ﹤0.01% 5487
2025
Q2 		$29.9K Sell
7,543
-3,334
-31% -$14.5K ﹤0.01% 5673
2025
Q1 		$75.9K Buy
10,877
+122
+1% +$1.11K ﹤0.01% 5238
2024
Q4 		$158K Buy
10,755
+8,684
+419% +$138K ﹤0.01% 4933
2024
Q3 		$39.6K Sell
2,071
-477
-19% -$9.15K ﹤0.01% 5426
2024
Q2 		$44.9K Buy
+2,548
New +$41K ﹤0.01% 5341

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wells Fargo's CTNM Position: Q2 2026 in Review

Wells Fargo opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 22,510 shares worth $369K. The stake represents ﹤0.01% of the portfolio and ranks #4824 among its holdings. This is a return to the name: Wells Fargo previously reported a position in CTNM as recently as Q3 2025.

Wells Fargo first reported a position in CTNM in Q2 2024 and has held it in 7 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Wells Fargo held 22,510 shares of Contineum Therapeutics worth $369K as of Q2 2026.
  • Contineum Therapeutics was a new Wells Fargo position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4824 holding.
  • Wells Fargo first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.